Article
Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2021
Nilsson Monique B, Robichaux Jacqulyne, Herynk Matthew H, Cascone Tina, Le Xiuning, Elamin Yasir, Patel Sonia, Zhang Fahao, Xu Li, Hu Limei, Diao Lixia, Shen Li, He Junqin, Yu Xiaoxing, Nikolinakos Petros, Saintigny Pierre, Fang Bingliang, Girard Luc, Wang Jing, Minna John D, Wistuba Ignacio I, Heymach John V
Abstract excerpt
INTRODUCTION: The treatment of patients with EGFR-mutant NSCLC with vascular endothelial growth factor (VEGF) inhibitors in combination with EGFR inhibitors provides a greater benefit than EGFR inhibition alone, suggesting that EGFR mutation status may define a patient subgroup with greater benefit from VEGF blockade. The mechanisms driving this potentially enhanced VEGF dependence are unknown. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.